Outside Counsel for $8.5 Billion Life Sciences Company
As outside counsel for an $8.5 billion life sciences company, led a team managing all aspects of IP strategy and execution for a $20 million annual R&D function. Represented the company in multiple M&A transactions over $200 million and advised senior leadership on major strategic decisions around new product launches, commercial partnerships and licenses.
Global Patent Strategy and Execution for Diagnostics Company
As outside counsel for a venture-backed diagnostics company, took on an existing patent estate and developed a multi-pronged protection strategy for a first-in-class clinical microbiology lab system along with key messages for leadership and investors; drove successful U.S. and foreign prosecution to obtain multiple grants offering diversified claim protection ahead of launch; and filed roughly 30 new patent families over two years to capture ongoing innovation driven by second-gen product development.
White Space Analysis and R&D Guidance for $120 Million Product Area
Guided R&D activities for $120 million product area for public life sciences company by analyzing patent landscape to identify white space and exclusivity opportunities.
Claim Strategy Formulation for Future Filings
Formulated claim strategies for flagship gene editing system and standardized approach for future filings at biotech startup.
Led IP Diligence Process with Series B Investors
Led IP diligence process with series B investors for biotech startup, including development of key messages on patentability and FTO.
Strategic Counsel to CEO, Board of Directors in IP Dispute
Counseled biotech startup CEO and board of directors through resolution of a dispute with a former board member concerning IP rights.
In-House Counsel to Leading Gene Editing Company
As in-house counsel for a leading gene editing company, led a $2 million/year patent preparation and analysis function that built layered protection for the company’s technology platform and therapeutic pipeline, and facilitated major transactions including public stock offerings and partnering of a first-in-class gene editing therapeutic program.
IP Integration Following $2 Billion Acquisition
Spearheaded IP integration for medical device manufacturer following $2 billion acquisition of urology assets, including management of incoming patent estate and negotiating early termination of license agreements.
$70 Million Purchase for Medical Device Manufacturer
Led IP due diligence for medical device manufacturer in $70 million purchase of interventional radiology assets.
Business Development Counsel in Relation to Partnerships with Early-Stage Companies
Counseled medical device manufacturer division’s business development team on IP dimensions of partnering deals with early-stage companies.